A phase I/II clinical trial in patients with colorectal cancer demonstrated that intramuscular injection of the NCI 4650 vaccine elicited CD8 and CD4 T cell responses to novel antigens, with no significant side effects or tumor recurrence (29). This evidence concerns the gene CD8A and neoplasm.